ArticleInternational journal of nanomedicine2010
Plasmid DNA delivery into MDA-MB-453 cells mediated by recombinant Her-NLS fusion protein.
Article in International journal of nanomedicine, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 19 citations in OpenAlex.
- Cell-Mediated and Peptide-Based Delivery Systems: Emerging Frontiers in Targeted Therapeutics.Pharmaceutics · 2025Review
- Antibiofilm Activity of Epinecidin-1 and Its Variants Against Drug-ResistantInfectious disease reports · 2024Article
- Expression and purification of epinecidin-1 variant (Ac-Var-1) by acid cleavage.Applied microbiology and biotechnology · 2024Article
- Design and characterization of novel recombinant listeriolysin O-protamine fusion proteins for enhanced gene delivery.Molecular pharmaceutics · 2015Article
- Cell-penetrating peptides and their analogues as novel nanocarriers for drug delivery.BioImpacts : BI · 2015Review
- Current status of gene therapy for breast cancer: progress and challenges.The application of clinical genetics · 2014Review
- An efficient calcium phosphate nanoparticle-based nonviral vector for gene delivery.International journal of nanomedicine · 2011Article
- Structure prediction and validation of an affibody engineered for cell-specific nucleic acid targeting.Systems and synthetic biology · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A major rate-limiting step in nonviral gene delivery is the entry of nucleic acids across various membrane barriers and eventually into the nucleus where it must be transcribed. Cell-penetrating peptides and proteins are employed to generate formulations that overcome these challenges to facilitate DNA delivery into cells efficiently. However, these are limited by their inability to deliver nucleic acids selectively due to lack of specificity because they deliver to both cancer and normal cells. In this study, through modular design, we generated a recombinant fusion protein designated as Her-nuclear localization sequence (Her-NLS), where heregulin-α (Her), a targeting moiety, was cloned in frame with cationic NLS peptide to obtain a cell-specific targeting biomolecule for nucleic acid delivery. The heregulin-α(1) isoform possesses the epidermal growth factor-like domain and binds to HER2/3 heterodimers which are overexpressed in certain breast cancers. Purified recombinant Her-NLS fusion protein binds plasmid DNA and specifically transfects MDA-MB-453 cells overexpressing the epidermal growth factor receptors HER2/3 in vitro. The approach described would also permit replacement of heregulin ligand with other targeting moieties that would be suited to cell-specific nucleic acid delivery mediated via receptor-ligand interactions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.